Connecticut 2023 Regular Session Status: In Committee

HB 6830 — AN ACT ESTABLISHING A PRESCRIPTION DRUG AFFORDABILITY ADVISORY COUNCIL.

Last action — FILE NO. 365

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill died with 2023 Regular Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.

Bill Text

What changed in the latest version

118 added · 83 removed

118 line(s) added, 83 removed.

→
Previous
Latest
General Assembly Raised Bill No.
House of Representatives General Assembly File No.
6830 January Session, 2023 LCO No.
365 January Session, 2023 Substitute House Bill No.
3985 Referred to Committee on INSURANCE AND REAL ESTATE Introduced by:
6830 House of Representatives, April 3, 2023 The Committee on Insurance and Real Estate reported through REP.
(INS) AN ACT ESTABLISHING A PRESCRIPTION DRUG AFFORDABILITY BOARD.
WOOD of the 29th Dist., Chairperson of the Committee on the part of the House, that the substitute bill ought to pass.
AN ACT ESTABLISHING A PRESCRIPTION DRUG AFFORDABILITY ADVISORY COUNCIL.
(NEW) (Effective October 1, 2023) (a) As used in this section:
(NEW) (Effective October 1, 2023) (a) (1) There is established within the Health Care Cabinet of the Office of Health Strategy, established under section 19a-754a of thegeneral statutes, aPrescription Drug Affordability Advisory Council, which shall:
(1) "Biologic" means any drug licensed under 42 USC 262, as amended from time to time;
(A) Provide recommendations on any policy initiatives of the Health Care Cabinet;
(2) "Biosimilar" means any drug that is similar to a biologic and is produced or distributed in accordance with a biologics license application approved under 42 USC 262, as amended from time to time;
and (B) review and advise the Health Care Cabinet with respect to health care cost initiatives in this state, including, but not limited to, cost trendsinhospitals,pharmaceuticalcostsandpricing,pharmacybenefits managers' costs to the health care system and costs associated with health care provider billing.
(3) "Board" means the Prescription Drug Affordability Board established pursuant to this section;
(2) For the purposes of this section, "chain pharmacy" means any community pharmacy that is publicly traded or has not less than six stores located in this state.
(4) "Chain pharmacy" means any community pharmacy that is publicly traded or has not less than six stores located in this state;
(b) The advisory council shall consist of the following members:
(5) "Community pharmacy" means any pharmacy licensed under section 20-594 of the general statutes that stores and dispenses legend drugs, as defined in section 20-571 of the general statutes, and legend LCO No.
sHB6830 / File No.
3985 1 of 5 Raised Bill No.6830 devices, as defined in said section, and from which related pharmaceutical care services are provided primarily to noninstitutionalized patients living in a community setting;
365 1 sHB6830 File No.
(6)"Genericdrug" means(A)any drugthat ismarketedordistributed in accordance with an abbreviated new drug application approved under 21 USC 355, as amended from time to time, (B) any generic drug as defined in 42 CFR 447.502, as amended from time to time, or (C) any drug that entered the market before calendar year 1962 that was not originally marketed under anewprescriptiondrug product application;
365 (1) Two appointed by the speaker of the House of Representatives, one of whom shall be a representative of the American Association of Retired Persons, and one of whom shall be a representative of the health insurance industry;
(7) "Independent pharmacy" means any privately owned pharmacy that has five or fewer stores located in this state;
(2) Two appointed by the president pro tempore of the Senate, one of whom shall be a representative of a labor union in this state, and one of whom shall be a member of any state-wide health care advocacy coalition;
(8) "Office of Health Strategy" means the Office of Health Strategy established under section 19a-754a of the general statutes;
(3) Two appointed by the majority leader of the House of Representatives, one of whom shall be a representative of a large business and employer community in this state, and one of whom shall be a pharmacist licensed under chapter 400j of the general statutes and employed by any chain pharmacy;
(9) "Pharmacist" has the same meaning as defined in section 20-571 of the general statutes;
(4) Two appointed by the majority leader of the Senate, one of whom shall be a representative of a pharmaceutical manufacturer, and one of whom shall be a representative of the provider community;
and (10) "Prescription drug product" means a brand-name drug, a generic drug, a biologic or biosimilar.
(5) Two appointed by the minority leader of the House of Representatives, one of whom shall be a member of the biotechnology industry, and one of whom shall be a member of the small business community in this state;
(b) There is established a Prescription Drug Affordability Board, which shall be part of the Office of Policy and Management for administrative purposes only.
(6) Two appointed by the minority leader of the Senate, one of whom shall be a representative of the medical device industry, and one of whom shall be a member of a chamber of commerce in this state;
(c) The board shall consist of the following members:
(7) Two appointed by the Governor, with the advice and consent of both houses of the General Assembly, one of whom shall be a representative of any state-wide health care advocacy coalition, and one of whom shall be a representative of the employer community in this state;
(1) One appointed by the speaker of the House of Representatives, who shall be a representative of the American Association of Retired Persons;
(2) One appointed by the president pro tempore of the Senate, who shall be a representative of a state-wide health care advocacy coalition;
(3) One appointed by the majority leader of the House of Representatives, who shall be a pharmacist licensed under chapter 400j LCO No.
3985 2 of 5 Raised Bill No.6830 of the general statutes and employed by any independent pharmacy;
(4) One appointed by the majority leader of the Senate, who shall be a pharmacist licensed under chapter 400j of the general statutes and employed by any chain pharmacy;
(5) One appointed by the minority leader of the House of Representatives, who shall be a person sixty-five years of age or older;
(6) One appointed by the minority leader of the Senate, who shall be a person sixty-five years of age or older;
(7) One appointed by the Governor, with the advice and consent of both houses of the General Assembly, who shall be a representative of any state-wide health care advocacy coalition;
(d) No member of the board appointed pursuant to subsection (c) of this section may be a member of the General Assembly.
sHB6830 / File No.
(e) All initial appointments to the board shall be made not later than January 1, 2024.
365 2 sHB6830 File No.
Board members shall serve for a term of four years.
365 (c) No member of the advisory council appointed pursuant to subsection (b) of this section may be a member of the General Assembly.
No board member shall be appointed to more than two terms.
(d) All initial appointments to the advisory council shall be made not later than January 1, 2024.
Advisory council members shall serve for a term of four years.
No advisory council member shall be appointed for more than two terms.
Any vacancy occurring other thanby expirationoftermshall be filled for thebalance ofthe unexpired term.
Any vacancy occurring other than by expiration of term shall be filled for the balance of the unexpired term.
(f)TheGovernor shallselectthechairpersonoftheboardfromamong the members of the board.
(e) The Governor shall select the chairperson of the advisory council from among the members of the advisory council.
Such chairperson shall schedule the first meeting of the board, which shall be held not later than March 1, 2024.
Such chairperson shall schedule the first meeting of the advisory council, which shall be held not later than March 1, 2024.
The board shall meet not less than quarterly and at such other times as such chairperson deems necessary or upon the request of a majority of such members.
The advisory council shall meet not less than quarterly and at such other times as such chairperson deems necessary or upon the request of a majority of such members.
(g) A majority of the board shall constitute a quorum for the transaction of any business.
(f) A majority of the advisory council shall constitute a quorum for the transaction of any business.
LCO No.
(g) The members of the advisory council shall serve without compensation, but shall, within the limits of available funds, be reimbursed for expenses necessarily incurred in the performance of their duties.
3985 3 of 5 Raised Bill No.6830 (h) The members of the board shall serve without compensation, but shall, within the limits of available funds, be reimbursed for expenses necessarily incurred in the performance of their duties.
(h) Not later than January 1, 2025, and annually thereafter, the advisory council shall submit a report to the Office of Health Strategy and, in accordance with the provisions of section 11-4a of the general statutes, to the joint standing committee of the General Assembly having cognizance of matters relating to insurance.
Show all 102 changed rows (62 more)
Previous
Latest
(i)Theboardshallhave thefollowing powers andduties:
(1) Conduct annual reviews of prescription drug product usage in this state to identify any prescription drug products that may create affordability challenges for the health care system in this state;
(2) obtain data from the Office of Health Strategy as necessary and available to carry out the purposes of this section;
(3) establish bylaws to govern such board's procedures;
and (4) perform such other acts as may be necessary and appropriate to carry out the duties described in this section.
(j) In order for the board to carry out the provisions of subsection (i) of this section, the Office of Health Strategy shall provide to such board, not later than thirty days following the end of each calendar quarter commencing on January 1, 2024, a list of all prescription drug products obtained by the Office of Health Strategy pursuant to section 19a-754b of the general statutes that are marketed in the state during the previous calendar year.
(k) Not later than January 1, 2025, and annually thereafter, the board shall submit a report, in accordance with the provisions of section 11-4a of the general statutes, to the joint standing committee of the General Assembly having cognizance of matters relating to insurance.
The report shall include, but need not be limited to:
(1) The results of the annual review conducted pursuant to subsection (i) of this section;
(2) price trends for prescription drug products in this state;
and (3) any recommendations such board may have on further legislation neededto make prescription drug products more affordable in this state.
Section 1 October 1, 2023 New section LCO No.
Section 1 October 1, 2023 New section INS Joint Favorable Subst.
3985 4 of 5 Raised Bill No.
sHB6830 / File No.
6830 Statement of Purpose:
365 3 sHB6830 File No.
To establish a prescription drug affordability board to monitor prescription drug pricing in this state.
365 The following Fiscal Impact Statement and Bill Analysis are prepared for the benefit of the members of the General Assembly, solely for purposes of information, summarization and explanation and do not represent the intent of the General Assembly or either chamber thereof for any purpose.
[Proposed deletions are enclosed in brackets.
In general, fiscal impacts are based upon a variety of informational sources, including the analyst’s professional knowledge.
Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.] LCO No.
Whenever applicable, agency data is consulted as part of the analysis, however final products do not necessarily reflect an assessment from any specific department.
3985 5 of 5
OFA Fiscal Note State Impact:
Agency Affected Fund-Effect FY 24 $ FY 25 $ Office of Health Strategy IF - Cost 145,000 1 148,0002 Note:
IF=Insurance Fund Municipal Impact:
None Explanation The bill, which establishes a 15-member Prescription Drug Affordability Advisory Council within the Health Care Cabinet of the Office of Health Strategy, results in a cost of $145,000 in FY 24 and $148,000 in FY 25 to OHS for salary and fringe benefits related to hiring one Planning Analyst to support the administrative activities of the council.
The Out Years The annualized ongoing fiscal impact identified above would continue into the future subject to inflation.
Sources:
Department of Administrative Services website The fringe benefit costs for employees funded out of other appropriated funds are budgeted within the fringe benefit account of those funds, as opposed to the fringe benefit accounts within the Office of the State Comptroller.
The estimated active employee fringe benefit cost associated with most personnel changes for other appropriated fund employees is 103.41% of payroll in FY 23.
2Assumed growth of 2.5% in FY 25.
sHB6830 / File No.
365 4 sHB6830 File No.
365 OLR Bill Analysis sHB 6830 AN ACT ESTABLISHING A PRESCRIPTION DRUG AFFORDABILITY ADVISORY COUNCIL.
SUMMARY This bill establishes a 15-member Prescription Drug Affordability Advisory Council withinthe HealthCare Cabinet oftheOffice ofHealth Strategy (OHS)to (1) make recommendationsto the cabinet on its policy initiatives and (2) review and advise the cabinet on health care cost initiatives, including cost trends in hospitals, pharmaceutical costs and pricing, pharmacy benefit mangers’ costs to the health care system, and costs associated with health care provider billing.
Beginning by January 1, 2025, the advisory council must annually report (presumably, on its review and recommendations) to OHS and the Insurance and Real Estate Committee.
EFFECTIVE DATE:
October 1, 2023 ADVISORY COUNCIL MEMBERSHIP The advisory council has the following members:
1.
two appointed by the House speaker, one who represents the American Association of Retired Persons, and one who represents the health insurance industry;
2.
two appointed by the Senate president pro tempore, one who representsa labor unioninConnecticut and onewho isamember of a state-wide health care advocacy coalition;
3.
two appointed by the House majority leader, one who represents a large business and employer community in the state, and the other who is a Connecticut-licensed pharmacist employed at a chain pharmacy (i.e., a community pharmacy that is publicly sHB6830 / File No.
365 5 sHB6830 File No.
365 traded or has at least six in-state locations);
4.
two appointed by the Senate majority leader, one who represents a pharmaceutical manufacturer and the other who represents the provider community;
5.
two appointed by the House minority leader, one who is a member of the biotechnology industry, and one who is a member of the Connecticut small business community;
6.
two appointedby the Senate minority leader, one who represents the medical device industry and one who is a member of a chamber of commerce in Connecticut;
7.
two appointed by the governor, with legislative approval, one who represents any state-wide health care advocacy coalition, and one who represents the employer community in Connecticut;
and 8.
the OHS executive director or her designee.
The bill prohibits the appointed members from being members of the General Assembly.
Initial appointments must be made by January 1, 2024, and members serve up to a maximum of two, four-year terms.
Vacancies are filled by the appointing authority (and vacancies for reasons other than an expired term are filled for the remainder of the unexpired term).
The governor selects the chairperson from the council’s members, who must schedule the council’s first meeting to be held by March 1, 2024.
The council must meet at least quarterly, and more often as the chair deems necessary or upon a request of a majority of its members.
A majority of the council constitutes a quorum.
Councilmembers serve without compensation, but must be reimbursed, within available funds, for expenses necessarily incurred while doing their duties.
sHB6830 / File No.
365 6 sHB6830 File No.
365 COMMITTEE ACTION Insurance and Real Estate Committee Joint Favorable Substitute Yea 12 Nay 0 (03/16/2023) sHB6830 / File No.
365 7
⬇ Download PDF
View plain text versions (3)

Action History

  1. FILE NO. 365

  2. HOUSE CALENDAR NUMBER 252

  3. FAV. RPT., TABLED FOR HOUSE CALENDAR

  4. RPTD. OUT OF LCO

  5. REFERRED TO Office of Legislative Research AND Office of Fiscal Analysis 04/03/23

  6. FILED WITH LCO

  7. Joint Favorable Substitute

  8. PUBLIC HEARING 0309

  9. REF. TO JOINT COMM. ON Insurance and Real Estate

Sponsors

  • Insurance And Real Estate Committee · Primary

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 186 not signed on

Sponsors (1)

  • Insurance And Real Estate Committee

Co-sponsors (0)

None.

Not signed on (186)

186 members have not signed on to this bill.

Show all 186 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors HB 6830?
HB 6830 is sponsored by Insurance And Real Estate Committee.
What is the current status of HB 6830?
This bill died with 2023 Regular Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track HB 6830?
Track HB 6830 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB 6830

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HB 6830

Last checked for changes 2 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →